US stock · figures in US dollars · scored on full-year results
Viatris Viatris Inc.
Viatris scores 36/100 on fundamentals: in the bottom 8% of 503 scored S&P 500 stocks. Its strongest area is Risk (70/100); its weakest is Business Strength (0/100). It carries 3 warning flags: Weak Spot, Recent Loss, Limited Data.
- Carries a Weak Spot flag
- Carries a Recent Loss flag
- Carries a Limited Data flag
An expensively priced stock with shrinking sales, but business strength needs attention.
Nearby peers
Ranks #54 of 60 in Healthcare by score
One-Minute Summary
Why Viatris scores 36
An expensively priced stock with shrinking sales, but business strength needs attention.
Business StrengthLowest pillar
0Why 0?
No data: Quarterly Momentum
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.
The company lost money in recent years: the bars below zero are losses, not profits.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales have stayed roughly flat over the last 8 quarters.
The company made a loss in at least one of the last 8 quarters: the bars below zero are losses, not profits.
Financial Safety
50Why 50?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings fell about 25.8% over 4 years: the company is steadily getting safer.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
38Why 38?
Show 3 charts
Operating vs Free Cash Flow
Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price Fairness
17Why 17?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 90.3% over the past year.
Risk
70Why 70?
No data: Quarterly Consistency
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Viatris (VTRS) scores 36/100 (Weak) on Score Your Stock's educational fundamentals model: in the bottom 8% of 503 scored S&P 500 stocks.
Its strongest pillar is Risk (70/100); its weakest is Business Strength (0/100).
Viatris ranks #54 of 60 scored Healthcare stocks on Score Your Stock.
Yes. Viatris (VTRS) has a dividend yield of 2.5%, from dividends with an ex-date in the last 12 months. Its Cash & Dividends pillar scores 38/100.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy VTRS. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Viatris (VTRS) is a Healthcare company (Drug Manufacturers - Specialty & Generic). On Score Your Stock's fundamentals check, it scores 36/100, rated Weak. Its biggest strength is Risk (70/100); its main watch-out is Business Strength (0/100). It also pays back about 2.5% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/vtrs-viatris
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 14.7b | US$ -410.7m | US$ 2.3b | US$ 1.8b | US$ -518.6m | US$ 886.5m | US$ 13.6b | US$ 1.7b | US$ 14.3b | US$ 10.1b | US$ 6.3b | US$ 35.0b | US$ 20.8b | US$ 3.9b | - | -3% | -3% | 1.0× | 1.6× | -0.4× | -136% | - | - | - |
| 2025 | US$ 14.3b | US$ -3.5b | US$ 2.3b | US$ 1.9b | US$ -465.1m | US$ 1.3b | US$ 14.7b | US$ 1.9b | US$ 14.7b | US$ 9.8b | US$ 7.1b | US$ 37.2b | US$ 22.5b | US$ 4.0b | US$ 48.0m | -24% | -25% | 1.0× | 1.4× | -6.8× | -16% | 4% | -4.0× | 1.0× |
| 2024 | US$ 14.7b | US$ -634.2m | US$ 2.3b | US$ 1.9b | US$ -359.1m | US$ 734.8m | US$ 14.3b | US$ 0.6m | US$ 18.6b | US$ 9.5b | US$ 5.8b | US$ 41.5b | US$ 22.9b | US$ 3.9b | US$ 48.0m | -3% | -4% | 0.8× | 1.7× | -0.1× | -91% | 4% | -21.5× | 0.7× |
| 2023 | US$ 15.4b | US$ 54.7m | US$ 2.9b | US$ 2.3b | US$ -574.9m | US$ 991.9m | US$ 18.4b | US$ 1.9b | US$ 20.5b | US$ 13.0b | US$ 7.8b | US$ 47.7b | US$ 27.2b | US$ 3.5b | US$ 48.0m | 0% | 0% | 0.9× | 1.7× | 1.4× | 1052% | 5% | 212.3× | 0.6× |